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Toxicity Tests in Animals: Historical Perspectives
and New Opportunities
Editor's Note: This article is thefirst ofa
three-part series that explores and evaluates
past, current, andfiuture uses ofanimals in
toxicity testing. The second article willfocus
on alternatives to animal models, and the
thirdwillattempttoprovidea balancedview
ofthe controversies surrounding the use of
animal data to predict human risksfrom
exposure to environmentalchemicals.
Toxicology, the study of the harmful
effects ofsubstances on living systems, has
been of interest since the earliest days of
science. From the dregs of Socrates' last
cup to the ominous silence of canaries
deep between the walls of mines, toxins
have been a fact of human existence. In
the seemingly endless quest to define all
life and ensure it against disease, hazards,
and unsafe practices, animals have re-
mained central to the search for answers
from ancestry, biology,
and environment. The
forearms ofGalen's Bar-
bary apes answered
questions about torn
gladiator muscles, while
his swine provided views
of mammalian cardio-
vascular physiology
which held for well over
1300 years. Centuries
later, innovative breed-
ers delighted Victorian
children with new color
combinations of mice,
giving rise to the trans-
genic biology that now George Gray-Ar
sheds light on some of because wewantt
science's most difficult
questions.
George Gray, of the Harvard Center
for Risk Analysis, cites animal models for
their important role in safety evaluation.
"Animal tests are used because we want to
be proactive about protection from haz-
ards; we want to prevent hazards rather
than wait to find them and use humans as
the experimental species."
A variety ofstudies define present-day
toxicity testing as laboratory animal sci-
ence and new biotechnologies are har-
nessed to address regulatory concerns
about safety. The impetus for toxicity
testing began in the early twentieth centu-
ry as vaccines, toxins, and serums were
introduced into an increasingly mobile
nim
top
society, one in which people moved away
from direct access to fresh food, and in
the direction of notoriously poor stan-
dards of food processing. Spoilage placed
many people at risk of death, and al-
though numerous scientists decried the
hazards of introducing chemicals into
meat and other foods, it was Upton
Sinclair's TheJungle that helped foster the
passage ofthe 1906 Food and DrugAct.
In addition to legislating safe practices
for the preservation of food, the Food
and Drug Act recognized that new vac-
cines carried hazards and attempted to
stem the tide ofquack medicines, tonics,
and elixirs. Simple admonitions about the
virtues ofhonest labeling, however, could
not protect public health. In 1937, when
the Massengill Company in Bristol,
Tennessee, marketed one of the earliest
antibiotics, sulfanilamide, with a sugar-
flavored solvent of
C _ deadly diethylene gly-
_ col, more than 100 peo-
. pie died before the
Food and Drug Admin-
istration tracked down
all samples of the drug
and halted its produc-
tion. A consequence of
this tragedy was the
Food, Drug and Cos-
metic Act of 1938, a
landmark in drug regu-
lation.
A number of
amendments to the
al tests are used Food, Drug, and Cos-
reventhazards. metic Act have been
passed over the years,
including the increasingly controversial
Delaney Clause, which specifies that no
substance that induces cancer in any ani-
mal may be incorporated into food.
Debate about the clause centers around
the argument that quantitative techniques
are part of toxicity testing versus the
belief that a single cell or molecule of a
carcinogen can cause cancer. In authoriz-
ing the clause, Congressman Delaney
chose the more prudent course of action.
Sydney Green, director of FDA's Center
for Food Safety and Applied Nutrition,
criticizes the clause: "I do believe that
more and more scientists are coming
around to the view that we've got to do
something about the Delaney Clause.
Because even ifthere isn't a safe level per
se ofa carcinogen, there ought to be safe
levels at which risk is almost minimal,
and that's the issue. Delaney does not
even allow that."
Landmark amendments were added to
the Food, Drug and Cosmetic Act in
1962, after the thalidomide disaster, in
which 7000 European, Canadian, and
British infants born to women who took
the drug were malformed. The United
States had only 17 cases of such defects,
largely due to the efforts of FDA Medical
Officer Frances Kelsey, who kept the drug
out of general distribution pending more
rigorous safety testing. Despite her
efforts, thalidomide was distributed to
3760 women as part ofdrug studies. The
new Food, Drug and Cosmetic Act
defined requirements for informed con-
sent, FDA approval ofclinical testing, and
the important standard that new drugs
demonstrate their effectiveness as well as
their safety. The thalidomide disaster
made the need for testing teratological
effects ofnewdrugs tragically dear.
In addition to the Food, Drug and
Cosmetic Act, which continues to be
administered by the FDA, the 1976 Toxic
Substances Act, administered by the
Environmental Protection Agency, and
the 1960 Federal Hazardous Substances
Labeling Act, administered by the Con-
sumer Product Safety Commission, affect
toxicity testing and regulation. The feder-
al government centralized its toxicity test-
ing in 1978, when it established the
National Toxicology Program.
To date, more than 450 chemicals
have been tested by NTP, and the results
have been incorporated into the Carcin-
ogenic Potency Database (CPDB). The
CPDB project began in the late 1970s at
Lawrence Berkeley Laboratories, when a
large bodyofanimal datawas mostly inac-
cessible to the scientific community.
More than 4500 experiments on 1300
chemicals are now part ofthe CPDB, with
more studies being added. "A large body
ofliterature had accumulated in the scien-
tific community, but there was no way to
access the information easily and use it for
large-scale analyses of test results. Such a
capability assists in making predictions
from a mouse to a rat or checking the
reproducibility ofbioassays in same strain,
species, and sex," explains Lois Gold,
director of the CPDB project. Scientists
can access the CPDB before, during, and
after studies to more reliably develop pro-
tocols and interpret data.
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Methods and Species
Methods for exposing animals to chemicals
were introduced in 1918, nearly 150 years
after Joseph Priestley recorded the effects
of gases on research animals. Techniques
were more fully developed as scientists
connected toxic exposure to diseases such
as black lung in miners and scrotal skin
cancer in children who routinely swept
soot from eighteenth-century chimneys.
Guidelines for standardized approaches to
toxicity testing began to appear in the form
of acute, subacute, and chronic toxicity
studies in animals during the early and mid
1950s, just as pesticides and antibiotics
converged on post-war American life.
Exponential increases in the production of
new drugs, chemicals, and environmental
pollutants have compelled toxicology's race
to devise and use biotechnologies, while a
multitude of chemicals are screened for
carcinogenic, teratogenic, and mutagenic
activity, as well as toxicity to specific
organic systems.
The use of in vitro screening proce-
dures to test chemicals in the laboratory
before they are tested in animals has allevi-
ated some of the uncertainties associated
with in vivo analysis. Says Louis Sibal,
chief of the Office of
Laboratory Animal Re-
search at NIH, "Now
we do in vitro screening
tests when we're looking
for new [chemothera-
peutic] agents, which
helps minimize the
number of animals we
use. We found that
screening with animals
didn't seem to give us
very many new agents.
Doing it the other way,
we can pick up just as
many important chemo-
therapeutic agents so David Rail-In vit
therefore we use in vitro pletely duplicateto)
cultures oftumor cells."
Such in vitro sys-
tems have withstood
rigorous tests of time
and expertise. Says
Sibal, "The main thing
is that it's a valid way of
screening, and that's
something that has
evolved over alongperi-
od of time. For exam-
ple, the National Can-
cer Institute has about
22 cell cultures of hu-
man tumors growing in
vitro, and it took years
to develop all those. Linda Birnbaum-
You can feel a little bit model depends on
more secure when you asked.
ro ti
xic e
-Ch
the
screen an agent against=
those lines before you
go on to test it in ani-
mals. Ultimately, though,
we have to go into the
whole animal because
one cell has only a lim-
ited number of func-
tions."
David Rall, former
director of the Na-
tional Institute of En-
vironmental Health
Sciences and retired
assistant surgeon gener-
al, commented on the
relationship between in
vitro and in vivo tests:
"The biochemical pro- Nostrangerto toxic
cess leading from the used intoxicitytestii
administration of a
chemical to the toxic effect is so complex
that we really cannot duplicate it in vitro.
We can duplicate bits and pieces of the
process, which is why some of the muta-
tional assays in single cells or in bacteria
are very useful. In cancer, for instance,
you have initiation, promotion, and so
forth. You can look at any one ofthese in
an in vitro test, but you
can't put the whole thing
_ together in a way which
accurately duplicates the
process in the whole or-
ganism.
The choice of which
animal to use for a par-
ticular study is vitally
important. Although
nearly 90% of all ani-
mals used in research are
rats and mice, a number
of other mammals are
also used in studies, in-
cluding guinea pigs,
ests cannot com- dogs, cats, rabbits, and
3ffects. nonhuman primates.
There are many consid-
< erations to make when
O choosing a particular
species for toxicity test-
ing. "You choose your
animal model based upon
the question you are ask-
ing," explains Linda
Birnbaum, director of
Environmental Toxicol-
ogy, EPA.
Rats and mice are of-
ten used in the early sta-
ges of toxicity testing,
before it is clear what
questions to ask. After
hoice of animal some initial studies and
e question being with more data available,
other species may be in-
:itytesting. Rats and mice make up 90% ofthe animals
rng.
corporated into studies. Because studies
are done to predict the human response to
a chemical based on the results from non-
human animals, it often helps to repeat
studies from one species in another. "If
you get a similar kind of response, your
level ofconfidence starts to rise that this is
not only a rat response, it happens in more
kinds ofanimals than one," says Birnbaum.
Pharmacokinetics, the study of the
interactions between drugs and the body,
sheds light on the discrete molecular
responses to a toxic hazard such as dioxin.
Ultimately, such investigations enable
researchers to develop approaches that help
estimate risks to humans from exposure to
certain kinds ofchemicals.
Pharmacokinetic studies measure the
breakdown, distribution, and excretion of
chemicals in the body and highlight some
of the factors that regulate this process in
different organ systems. Certain questions
are best answered in certain species because
certain animals have unique physiological
variations that define their suitability for a
particular investigation.
ComparingAnimals with Humans
Frederica Perera, head of the Molecular
Epidemiology Program at Columbia Uni-
versity, combined classic epidemiological
techniques and bioassays to assess the
effects of exposure to polycyclic aromatic
hydrocarbons (PAHs) such as benzo[a]-
pyrene. Results of recent studies, pub-
lished in Nature, were based on measure-
ments of products of toxic exposure in
people living in the Silesian region of
Poland, a mining area with high concen-
trations ofbenzo[a]pyrene.
Bioassays are based on the fact that car-
cinogens, and toxins in general, enter the
body and change tissues, organs, cells, and
molecules. The changes, or markers, pro-
vide evidence of the effect of a particular
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carcinogen. The two
classes of markers are
those for dose and sus-
ceptibility. Whereas bio-
monitoring samples pop-
ulations for dose or re-
sponse markers, molecu-
lar epidemiology at-
tempts to construct a
relationship between
markers of dose or re-
sponse and cancer risk.
In the body, PAH
binds to DNA to form
PAH-DNA adducts, one Frederica Perera-
kind of biomarker that to extrapolate frc
can be detected using markersto humans
immunologic, fluorescent, or radioactive
labeling techniques. Other biomarkers
were assessed in Perera's study, including
visualizing chromosomes to look for dam-
age and assaying oncogenes, which regulate
cell growth. Perera and others are trying to
derive a relationship between PAH dose or
PAH-DNA concentration and the risk of
cancer. "Molecular epidemiology can give
us some sense of the potential risk in the
human population," says Perera. "We
don't want to wait to take action until we
see what the health outcome is to hu-
mans.
Responses in animals are compared
with data for humans. "Ultimately," says
Perera, "we can compare the exposure to
molecular dose, and dose to biological
effect, and biological effect to risk relation-
ships in both species." "But," she adds,
"we want to better understand how to
extrapolate from the human response in
markers to those in laboratory animals for
whom we know what the tumor incidence
is.
WholeAnimal Tests
There is a spectrum of toxicity tests using
whole animals, which evaluate chemical
hazards ranging from carcinogenicity to
teratology and reproduction studies, as well
as mutagenicity, neurotoxicity, and others.
The studies can be loosely categorized as
acute, subacute, subchronic, or chronic
toxicity tests. One acute test, the Draize
test, is used to determine whether sub-
stances that come into contact with the
skin and eyes will cause irritation or injury.
The eye test consists of placing drops of
the test substance in one eye of as few as
three test animals, generally rabbits, whose
eye sensitivity is comparable to that of
humans. Use of animals allows a twofold
process to occur, as the eye reacts to the
chemical and then begins to heal.
In the skin irritancy test, the substance
in question is placed on a patch of skin
-Un
omi
s iSac
that has been clipped of hair. One day
later the patch is removed, and the skin is
evaluated for up to three
_ additional days. In re-
_, sponse to concerns for
_ animal rights, fewer
E Draize tests are being
, conducted and fewer an-
imals are used in the
tests. In addition, since
its early use in the
1940s, the Draize tests
have been modified and
now use ophthalmic an-
esthetics, diluted solu-
tions, and lower doses so
nderstanding how as to reduce or eliminate
animal biological pain or distress in test
a majorgoal. animals.
The LD50 or acute lethality test is gen-
erally performed in rats or rabbits and uses
the dose ofchemical at which one-halfthe
test animals can be expected to die. New
approaches to the classic LD50 are current-
ly in practice that incorporate information
from preliminary in vitro screening tests.
The modified LD50, known as the range-
limit study, uses 6-10 animals instead of
80-100, as was the case before the mid-
80s. The classic LD50 test is now generally
used only to check the potency of highly
toxic chemicals, such as when screening for
potential chemotherapeutic agents or
determining the effective strengths ofpesti-
cides.
Multiple endpoint testing is an addi-
tional part of acute lethality studies and
includes observations ofabnormal behavior
during and after dosing, as well as autop-
sies that evaluate toxic effects seen in vari-
ous internal organs. The LD50 is often
viewed as analogous to an accidental expo-
sure to toxic substances. "We need acute
tests because we want to know how potent
the chemical is. In other words, ifpeople
are exposed in a single accident, what sort
oflethality is the chemical known to have?
You can also get an in-
dication ofsome ofthe
organ systems that are
affected-the brain,
the kidney, and so
forth," explains Rall.
Subacute and chron-
ic studies examine the
risks oflonger-term ex-
posures to chemicals
and drugs and include
long-term carcinogene-
sis studies for cancer
testing. Subacute tests
evaluate the effects of
three different doses in
two different animal
species and involve
administration of the
substance via the same Immunoglobulin fac
route as human expo- in addition to being L
sure. Results ofLD50 tests help determine
which of the three ioses given in an acute
toxicity test is safe, and which dose is lethal
in no more than 10% ofthe animals.
"The subacute or subchronic test gives
a lot ofinformation about the general toxi-
cology: Does it affect the kidneys, bladder,
brain, liver, and so on. If so, how? This
all requires very careful testing, very good
observation of the animals, and expensive
pathology at the end ofthe test," says Rall.
Subacute evaluations, generally 90 days
long, provide the final safety tests for most
consumer and household products not
intended for consumption.
Chronic studies are often conducted in
rats and assess the effects of long-term
exposure to a substance. When humans
are expected to be exposed to a chemical
for the duration of a lifetime, the chronic
studies extend over the animal's lifetime,
which for rats is about two years. A great
many chronic toxicity tests are carcino-
genicity studies, in which both sexes oftwo
species are administered the substance in
question. The dose given is referred to as
the maximum tolerated dose (MTD), the
dose that does not shorten the life span of
the animal or cause overt signs of toxicity
or a weight decrease of more than 10%.
NTP protocols for chronic studies general-
ly require that two to three doses be given:
the MTD, one-half the MTD, and, more
recently, one-quarter the MTD. Two-year
chronic carcinogenicity studies are among
the most costly toxicity studies, with cur-
rent estimates of $2 million for oral-dose
experiments and $3 million for inhalation
experiments. Moreover, chronic studies
require toxicologists to make two extrapo-
lations, and therein lie the difficulties.
"The question becomes what are we find-
ing out in the long-term studies, and what
is it we want to know?" says Gold. There is
increasing awareness that cancer is not nec-
ctory. Rabbits are frequently used to raise antibodies
used in sensitization tests.
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essarily the only health hazard that may be
caused by chemical exposures. Bioassays
such as those conducted by the NTP now
look at other toxic effects including repro-
ductive, developmental, immunotoxicity,
and neurotoxicity.
The first extrapolation to be made in
chronic studies is the more qualitative
interspecies extrapolation. Because hu-
mans are rarely available, the species
extrapolation has been studied by looking
at the predictions between rats and mice,
which are closely related. By examining the
ability to predict carcinogenicity between
rats and mice, and relating, as well, the tar-
get organs for incidence of tumors, Gold
found that 75% ofthe time, if a chemical
is positive for tumors for a rat, it will be
positive in mice, and 50% ofthe time the
target organ is the same in both species.
Extrapolation from rats to humans is
unlikely to be more accurate than that.
The second type of extrapolation re-
lates to the fact that humans are usually
exposed to low doses of carcinogens, not
the high doses typified by even one-quarter
the MTD. Giving low doses of cancer-
causing agents to rodents would require
millions of animals to detect an effect.
The costs of such an approach to long-
term studies are enormous, and thus proto-
cols generally use only high doses of the
chemicals being studied. Although rodent
studies have provided data useful in toxici-
ty testing, the emerging tools of molecular
biology may offer some new opportunities
to study the mechanisms whereby chemi-
cals cause cancer and other adverse health
effects.
New Horizons
Ray Tennant, chief of the Experimental
Carcinogenesis and Mutagenesis Branch,
NIEHS, has one of the first transgenic
mouse lines specifically developed to inves-
tigate the molecular basis of chemical
mutagenesis. "Over a decade ago Bruce
Ames genetically engineered Salmonella
and created a line ofSalmonella that never
existed before and was quite chemically
sensitive. We used that tool to learn a lot
about biological and chemical effects. It
took a lot longer to learn how to genetical-
ly engineer the mice. But it is an equiva-
lent process and we stand to learn even
more using the genetically engineered
rodents," says Tennant.
Transgenic mice are the result of ad-
vanced techniques in cell and embryo cul-
tures, and their production involves the
labor-intensive process of microinjecting
DNA into the nuclei of fertilized eggs, a
process which in mice may yield 20-50
animals. The value of transgenics is that
investigators can change a single gene at a
time, then observe the animal for changes
in toxic response. This technology is
"spectacularly valuable for identifying pos-
sible mechanism whereby environmental
agents will cause disease," says James Huff
ofNIEHS's Environmental Carcinogenesis
Program.
The first transgenic mice were injected
with genes implicated in the development
of cancer, and they showed a high inci-
dence of certain kinds of tumors. A num-
ber of transgenic strains have been devel-
oped specifically for the purpose ofstudy-
ing aspects of tumor growth, including
cell proliferation and differentiation.
"Cancer is a consequence of certain
properties, the expression ofwhich is high-
ly dependent on the genotype of the ani-
mal that's exposed to a chemical. That's
where transgenic biology comes in: either
to insert specific genes, to regulate the
expression of specific genes, or to knock
out the function of certain genes. All of
these provide important ways to identify
critical target genes,"explains Tennant.
"An enormous number of genes influence
how individuals, strains or populations
respond to chemicals. We have a very poor
understanding ofthat."
The new "knockout" technology allows
researchers to alter or remove a specific
gene and observe the results. The tumor-
suppressor gene p53 was recently deactivat-
ed in mice, with the end result that al-
though they survived and grew, more than
70% of the mice developed tumors. Sci-
entists think that p53 signals when DNA is
damaged, causing the cell not to make
more DNA until it repairs the damaged
DNA. Cells change in the absence ofsuch
a signal, and the result may well be that
they are transformed into tumor cells.
Not surprisingly, transgenics are diffi-
cult to create, and getting a sturdy line of
mice requires extreme care. "Some of the
transgenes are unhealthy and do not do
well. It takes a great deal ofcare to come
up with a line that is healthy, viable, and
useful," says Tennant.
Model Care
Both traditional and transgenic animals
require specialized care and attention.
Many laboratory animals are special strains,
with tendencies toward disease which range
from specific types of tumors to increased
risk of infections. "When using highly
inbred mice, their resistance is down when
compared to a street-caught mouse," says
Birnbaum. "You can wipe out an entire
colony quite quickly ifyou introduce some
sort of common animal virus, on your
shoes, for example. Even if they survive,
you have compromisedyourdata."
A variety of mechanisms ensure good
animal practice in research. All Public
Health Service-funded projects must com-
ply with the Animal Welfare Act and and
the Health Research Extension Act, laws
that protect research animals. The policy
statement, "Public Health Service Policy
on Humane Care and Use of Laboratory
Animals" and the well-known Guideforthe
Careand UseofLaboratoryAnimalsprovide
specific methods of animal care. Insti-
tutional Animal Care and Use Committees
oversee animal practices at all Public
Health Service-funded facilities through-
out the country. The U.S. Department of
Agriculture, through its Animal and Plant
Health Inspection Service, inspects all non-
government facilities using animals other
than rats, mice, and birds under Public
Health Service funding.
The American Association for Accred-
itation of Laboratory Animal Care evalu-
ates animal programs across the country.
Although applying for accreditation is vol-
untary, more than 550 animal programs
throughout the United States, Canada, and
Europe are accredited through the pro-
gram, ranging from industry to govern-
ment to hospital facilities.
The American Association of Labor-
atory Animal Science coordinates aspects
of its training and certification program
with the American Veterinary Medicine
Association. "Our students go across the
board-in universities, private practice,
production facilities, any place an animal
lab is used," said AALAS President Richard
Knauff.
As science and ethics havejoined hands
to develop and refine laboratory animal
science, toxicologists have continued to
rely on live animal models for toxicity test-
ing. Mendelian genetics and Darwinian
theories of evolution have added impetus
to this reliance on animal models. From
dinosaurs and giant squid to RNA-directed
protein synthesis and nerve conduction,
evolution has manifested a striking conti-
nuity between seemingly distinct organ-
isms. Late twentieth-century technologies
capitalize on both the sophisticated inte-
gration ofwhole organ systems and evolu-
tionary continuity, with models ranging
from mice and bacteria to tissue cultures
and computerized simulations of whole
animal physiology. Ultimately, live animal
models continue to provide the knowledge
necessary to protect us from toxic effects,
which is toxicology's highest goal.
MaryWeideman
Mary Weideman is a freelance writer in Bethesda,
Maryland.
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